NCT04895748 - DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

March 6, 2026

Study Completion Date

March 6, 2026

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

DFF332

Hif2alpha inhibitor

DRUG

RAD001

mTOR inhibitor

DRUG

PDR001

anti-PD-1

DRUG

NIR178

Adenosine A2A antagonist receptor

Trial Locations (11)

Memorial Sloane Ketterin Cancer Ctr, New York

Novartis Investigative Site, Milan

WA Uni School Of Med, St Louis

Uni Of TX MD Anderson Cancer Cntr, Houston

City of Hope National Medical, Duarte

Novartis Investigative Site, Villejuif

Novartis Investigative Site, Singapore

Massachusetts General Hospital, Boston

Novartis Investigative Site, Brno

Novartis Investigative Site, Koto Ku

Novartis Investigative Site, Barcelona